cancer detection News
-
IONIQ Sciences announces IP acquisition and License buyou
ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that it has acquired from OT Acceptance, LLC (“OT Acceptance”) certain intellectual property formerly licensed to the Company by OT Acceptance. With this acquisition, the Company now owns (rather than licenses) all of the intellectual property used by it with respect to early ...
-
Rocío Arroyo, CEO of Amadix, has been chosen as one of the protagonists of change in 2022 in the list made by Forbes.
This year, the specialized magazine has selected 22 people, including Rocío Arroyo, who stand out for their talent, leadership, productivity, and power to change the world. Rocío Arroyo has been distinguished by her professional career as scientific, researcher and entrepreneur in the oncologic field with the development of early cancer detection tests by Amadix. Read the ...
By Amadix
-
IONIQ Sciences hires Edison Group as Investor Relations Advisor
IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that it has hired Edison Group, a leading investor relations and research firm, to assist with its investor relations program. Edison Group, established in 2003, is an investor relations, investor research, and consulting firm. With broad sector knowledge, analyst resources and deep capital markets expertise, ...
-
IONIQ Sciences submits De Novo application to FDA for IONIQ ProLung Test
IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that it has filed a De Novo application with the U.S. Food and Drug Administration (the “FDA”) for its IONIQ ProLung Test™ used for lung cancer. Mr. Jared Bauer, IONIQ Sciences CEO, stated, “Today we submitted our De Novo application for marketing clearance to the FDA for our IONIQ ...
-
IONIQ Sciences is awarded “Best of Salt Lake City – Cancer Testing 2021”
IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is honored to announce it has been awarded “Best of Salt Lake City – Cancer Testing 2021.” We are humbled to have our mission to modernize early-stage cancer detection continue to be recognized nationally and locally. Through our novel application of bioimpedance technology, we believe that we’re ...
-
Transpara breast AI reduces false positives and radiologists` workload in largest Danish screening programme
The team running the country's largest breast screening programme have shown that using Transpara breast AI further confirmed the enormous contribution of this technology to breast cancer detection: not only to reduce the number of false positives but also to reduce radiologists' workload by over 60%. In Copenhagen, the biannual breast screening programme for women aged from 50 to 69, has been ...
-
GRAIL Statement on President Biden’s Bold Initiative to Reignite the Cancer Moonshot
“We applaud President Biden for reigniting the Cancer Moonshot and highlighting the critical role of early detection in achieving the ambitious, but attainable, goal of reducing the cancer death rate by at least 50 percent in the next 25 years. Improving quality of life for patients and survivors, while addressing inequities in access to cancer screening, diagnostics and treatment is a ...
By Grail, Inc.
-
IONIQ Presents Lung Cancer Trial Results at ATS 2022
IONIQ Sciences is proud of our team members who presented our latest lung cancer clinical trial results in a poster today at the American Thoracic Society meeting in San Francisco, CA. This was a great honor to highlight our growing bioimpedance clinical evidence that continues to demonstrate the possibility of a non-invasive, low-cost, early-stage lung cancer diagnosis. Furthermore, the ...
-
NIH/NCI Small Business Innovation Research Grant, Awarded Fall 2019
Nodexus was selected for an SBIR grant for the development of a novel cancer stem cell detection and isolation platform leveraging the core Nodexus technology ...
By Nodexus Inc.
-
FlavourSpec feasibly detects hepatocellular carcinoma urinary biomarkers in clinical practice
The Imspex Group’s proprietary gas chromatography-ion mobility spectrometry (GC-IMS) technology was part of a ground-breaking cancer detection study that was recently carried out by a team of researchers from the University of Warwick, Coventry University and the University of Leicester. In this study, the FlavourSpec® headspace analysis device showed that volatile organic compounds ...
-
Knight Cancer Institute at Oregon Health & Science University to Offer the Galleri® Multi-Cancer Early Detection Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU) to offer Galleri®, GRAIL’s multi-cancer early detection (MCED) blood test. OHSU will provide patients access to Galleri via a pilot program to help find signals of cancer in earlier stages and advance ...
By Grail, Inc.
-
Avelas Biosciences Presents Phase 2, Period 2 Data in Virtual Poster Session at the 22nd Annual Meeting of The American Society of Breast Surgeons
SAN DIEGO, CA – Avelas Biosciences, Inc., a pioneer in the field of fluorescence imaging for real-time cancer detection, presented the results from Period 2 of its most recent clinical trial in a virtual poster session at the 22nd Annual Meeting of The American Society of Breast Surgeons. The poster, titled “Pegloprastide Based Ratiometric Fluorescence Imaging Detects Intraoperative ...
-
Cancer Prevention and Early Detection Is One Step Closer as Universal DX Announces Breakthrough Study Results from Its Multi-omics + Computational Biology + Machine Learning Blood Tes
New results from the OMICS study, which will be presented atASCO, show Universal DX's blood test can detect colorectal cancer with extraordinary accuracy (92% sensitivity / 97% specificity), which exceeds currently available non-invasive tests for colorectal cancer screening Early detection cancer screening via a liquid biopsy is not only critical to save lives, but is a vast market opportunity, ...
-
GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test. Based in Orange, ...
By Grail, Inc.
-
Rezolut and CureMetrix Embark on AI Innovation Partnership
Rezolut, LLC and CureMetrix, Inc. have launched a pilot program in the Greater New York City area with the aim of pairing advanced technology with operational excellence to improve breast cancer detection in women receiving routine screening mammograms. Rezolut, LLC is a national, emerging platform of diagnostic medical imaging services, serving patients across the United States with 23 ...
-
Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells ...
-
Illumina to Acquire GRAIL to Launch New Era of Cancer Detection
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered single digit ...
By Grail, Inc.
-
Edinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer
Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment of Dr Bernhard Sixt as Chief Executive Officer, effective immediately. Dr Sixt has 30 years of healthcare industry experience in the development and commercialisation of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham ...
-
Scion Acquires Soft Tissue Biopsy Product Line
June 15, 2012 – Newton, Massachusetts. Scion Medical Technologies, LLC (Scion), a company that manufactures and sells products in the general surgery area, announced today that it has acquired a suite of assets for soft tissue biopsy, including issued intellectual property for a novel approach in the field. Scion is completing the final stages of development of the product and plans to ...
-
The largest breast AI study to date shows value of Transpara in mammographic screening
The Cancer Registry of Norway is one of the oldest and most respected organisations of its kind in the world. It collects data and produces statistics of the cancer prevalence in Norway, has the administrative responsibility for the public screening programme in Norway and has an extensive research activity. In a recent study, the Registry used over 120,000 screening examinations from a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you